Yuce Bio is the first high-tech company in China to realize the industrialization of single-molecule immunodiagnosis technology. Recently, Yuce Biotech completed a round of financing of nearly 100 million yuan, led by Boyuan Capital, followed by Jianyi (formerly Sinopharm) Capital, and the old shareholder Puhua Capital and well-known industrial capital continued to raise. This round of financing will help Yuce Bio to create a closed loop of the clinical transformation industry chain of new biomarkers, and promote the in-depth development of hypersensitive biomarker detection technology and the clinical transformation process of new biomarkers.
This article is reproduced from: https://www.itjuzi.com/investevent/13309737
This site is for inclusion only, and the copyright belongs to the original author.